Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Sound and Delightful: 12 Nutritious Smoothie Recipes - 2Trump administration plan to reduce access to some student loans angers nurses, health care groups
- 3ISS astronaut evacuation shouldn't interfere with upcoming Artemis 2 moon mission, NASA chief says
- 4The EU Is Considering Lifting Tariffs on Chinese Electric Vehicles
- 5A definitive Burger Confrontation: Which One Rules?
- Setbacks in Texas and elsewhere put Republicans' redistricting hopes in doubt as key deadlines loom
- Addressing sleep apnea early might decrease chances of developing Parkinson's disease
- Eating Brie, Gouda, cheddar may lower dementia risk, new study says
- Tyler Childers' 'Snipe Hunt' 2026 Tour: How to get tickets, presale times, prices and more
- Bolsonaro says hallucinatory effects of meds made him tamper with ankle tag
- Explainer-Why are hepatitis B vaccines given to newborns?
- The Best Computer games for Multiplayer Fun
- CVS forecasts 2026 profit above estimates on strong performance
- Watch China's Shenzhou 22 rescue ship arrive at Tiangong space station (video)
